bioRxivMicrobiologyPreprint
Ambroxol and Ciprofloxacin Show Activity Against SARS-CoV2 in Vero E6 Cells at Clinically-Relevant Concentrations
G. S. Timmins, S. B. Bradfute, V. Deretic, S. Kumar, E. C. Clarke, C. Ye
Abstract
We studied the activity of a range of weakly basic and moderately lipophilic drugs against SARS CoV2 in Vero E6 cells, using Vero E6 survival, qPCR of viral genome and plaque forming assays. No clear relationship between their weakly basic and hydrophobic nature upon their activity was observed. However, the approved drugs ambroxol and ciprofloxacin showed potent activity at concentrations that are clinically relevant and within their known safety profiles, and so may provide potentially useful agents for preclinical and clinical studies in COVID-19.
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Moxidectin and ivermectin inhibit SARS-CoV-2 replication in Vero E6 cells but not in human primary airway epithelium cells
N. Dinesh Kumar, B. M. ter Ellen, … J. Smit·bioRxiv·May 17, 2021
- Combined prophylactic and therapeutic use maximizes hydroxychloroquine anti-SARS-CoV-2 effects in vitro
N. Clementi, E. Criscuolo, … N. Mancini·bioRxiv·Mar 29, 2020
- Anti-severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) potency of Mefloquine as an entry inhibitor in vitro
K. Shionoya, M. Yamasaki, … K. Watashi·bioRxiv·Nov 19, 2020
- Broad anti-coronaviral activity of FDA approved drugs against SARS-CoV-2 in vitro and SARS-CoV in vivo
S. Weston, C. M. Coleman, … M. Frieman·bioRxiv·Mar 25, 2020
- Berberine and obatoclax inhibit SARS-CoV-2 replication in primary human nasal epithelial cells in vitro
F. S. Varghese, E. van Woudenbergh, … R. P. van Rij·bioRxiv·Dec 23, 2020
- Low selectivity index of ivermectin and macrocyclic lactones on SARS-CoV2 replication in vitro argues against their therapeutic use for COVID-19.
C. Chable-Bessia, C. Boulle, … D. Muriaux·bioRxiv·Nov 1, 2021